Access Financial Services Inc. now owns 4,017 shares of the biopharmaceutical company’s stock worth $438,000 after acquiring an additional 309 shares during the period.

Source: https://www.americanbankingnews.com/2023/09/05/commonwealth-equity-services-llc-reduces-stock-position-in-horizon-therapeutics-public-limited-nasdaqhznp.html

Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,967 shares in the last quarter.

Source: https://www.americanbankingnews.com/2023/09/05/credit-suisse-ag-boosts-stake-in-dynavax-technologies-co-nasdaqdvax.html

Aer Therapeutics, an Irish-founded biopharmaceutical spin-out company developing treatments for lung disease, has announced the close of a $36m Series A funding round today (14 April).

Source: https://biztoc.com/x/3959a35649fc91d3?ref=ff

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.

Source: https://www.americanbankingnews.com/2023/01/11/albireo-pharma-nasdaqalbo-downgraded-by-cowen.html

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

Source: https://www.marketscreener.com/quote/stock/ARCUS-BIOSCIENCES-INC-42096830/news/Gilead-and-Arcus-Announce-Anti-TIGIT-Domvanalimab-Continues-to-Demonstrate-Consistent-Improvement-in-44034075/?utm_medium=RSS&utm_content=20230603

Assenagon Asset Management S.A. now owns 2,080,518 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 1,417,018 shares in the last quarter.

Source: https://www.etfdailynews.com/2023/10/23/deep-track-capital-lp-acquires-16230216-shares-of-nektar-therapeutics-nasdaqnktr/

Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock valued at $25,513,000 after acquiring an additional 18,345 shares during the period.

Source: https://www.etfdailynews.com/2023/07/09/fifth-third-bancorp-sells-297-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn/

Ballentine Partners LLC now owns 41,332 shares of the biopharmaceutical company’s stock worth $2,399,000 after purchasing an additional 1,116 shares in the last quarter.

Source: https://www.etfdailynews.com/2023/12/29/bristol-myers-squibb-nysebmy-shares-purchased-by-u-s-capital-wealth-advisors-llc/

Bank Julius Baer & Co. Ltd Zurich now owns 659,143,253 shares of the biopharmaceutical company’s stock worth $42,152,211,000 after acquiring an additional 658,377,716 shares during the period.

Source: https://www.etfdailynews.com/2023/12/15/greenfield-savings-bank-acquires-269-shares-of-bristol-myers-squibb-nysebmy/

Bellerophon Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

Source: https://www.americanbankingnews.com/2023/01/27/bellerophon-therapeutics-inc-nasdaqblph-short-interest-up-1450-0-in-january.html

Biogen is one of the key biopharmaceutical companies in developing and commercializing innovative treatments for people living with neurological and neurodegenerative diseases such as spinal muscular atrophy, multiple sclerosis, and Alzheimer's disease.

Source: https://seekingalpha.com/article/4575506-biogen-stock-what-to-do-ahead-of-q4-earnings?source=feed_all_articles

BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

Source: https://www.americanbankingnews.com/2023/01/03/artemis-investment-management-llp-cuts-stake-in-bioxcel-therapeutics-inc-nasdaqbtai.html

BlackRock Inc. now owns 10,006,966 shares of the biopharmaceutical company’s stock valued at $259,982,000 after purchasing an additional 83,291 shares during the last quarter.

Source: https://www.etfdailynews.com/2023/06/11/neuberger-berman-group-llc-increases-holdings-in-xencor-inc-nasdaqxncr/

BlackRock Inc. now owns 17,483,188 shares of the biopharmaceutical company’s stock valued at $681,145,000 after buying an additional 767,864 shares during the last quarter.

Source: https://www.americanbankingnews.com/2023/06/10/barclays-plc-has-15-90-million-position-in-royalty-pharma-plc-nasdaqrprx.html

But why don't biopharmaceutical companies buy their stock immediately after the FDA approves their drugs?

Source: https://seekingalpha.com/article/4636211-mullen-automotive-worst-yet-to-come?source=feed_all_articles

Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 138 shares during the period.

Source: https://www.americanbankingnews.com/2023/06/06/advisors-capital-management-llc-decreases-stock-position-in-gilead-sciences-inc-nasdaqgild.html

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

Source: https://www.dailypolitical.com/2023/01/11/cellectar-biosciences-nasdaqclrb-now-covered-by-stocknews-com.html

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States.

Source: https://www.americanbankingnews.com/2023/08/03/cerevel-therapeutics-nasdaqcere-price-target-lowered-to-41-00-at-hc-wainwright.html

Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock worth $3,446,000 after buying an additional 4,877 shares in the last quarter.

Source: https://www.americanbankingnews.com/2023/12/15/asset-dedication-llc-has-464000-stock-holdings-in-gilead-sciences-inc-nasdaqgild.html

Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company.

Source: https://www.americanbankingnews.com/2023/02/11/cyclacel-pharmaceuticals-nasdaqcycc-now-covered-by-stocknews-com.html